Emcure Pharmaceuticals Share Price Hits 10% Upper Circuit After Revised Guidance

On November 4, 2026, Emcure Pharmaceuticals Limited shares reached a 10% upper circuit post the announcement of its financial results for the quarter ended September 30, 2026. The company reported notable growth in both revenue and net profit metrics. 

Emcure Pharmaceuticals Q2 FY27 Financial Performance 

For the quarter ended September 30, 2026, consolidated net profit increased by 29.31% year on year to ₹325.06 crore. Total revenue grew by 24.3% to ₹2,820.40 crore. The domestic business recorded revenue of ₹1,155.30 crore, reflecting a 12% year on year growth.  

The international business accounted for 59% of consolidated revenue, reporting sales of ₹1,665.20 crore, which represents a 34.5% increase. 

Margin Metrics and Share Price Movement 

Earnings before interest, tax, depreciation and amortisation grew 23.6% year on year to ₹587.80 crore. EBITDA margins decreased by 11 basis points year on year to 20.8%. The gross profit margin decreased by 131 basis points to 59.5%.  

The share price reached a new high of ₹2,180.80 on BSE, surpassing the previous high of ₹2,101 recorded on September 18, 2026. In the calendar year 2026, the stock increased by 53%. 

Read More: KPI Green Energy Share Price in Focus as it Signs 300 MW Wind Power PPA with SJVN! 

Revised Management Guidance 

Following the quarterly performance, the management revised its full year FY27 revenue growth guidance to over 20%. The company also projected a 100 basis point improvement in EBITDA margins. 

Emcure Pharmaceuticals Share Price Performance  

As of November 04, 2026, at 12:06 PM, Emcure Pharmaceuticals share price on NSE was trading at ₹2,174.20, up by 10.00% from the previous closing price. 

Conclusion 

Emcure Pharmaceuticals reported a revenue of ₹2,820.40 crore and a net profit of ₹325.06 crore for the September 2026 quarter. The company also revised its full year guidance upwards based on these reported results. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.